Kotak Mahindra Mutual Fund · #149840
Kotak Manufacture in India Fund - Regular Plan - Growth
Equity · Sectoral/ Thematic · Regular · Growth
Regular TER: 2.08% · as of
5-year NAV · change the window using the controls in the rolling-returns card below ↓
2022-03-02 → 2026-10-21
Latest NAV
₹20.8510
as of 2026-10-21 · -1.68% vs 2026-10-19
Earliest NAV in archive
2022-03-02
AMFI archive begins Apr 2006
Trailing CAGR vs assigned benchmark
| Window | Scheme CAGR | Benchmark CAGR | Excess | Period |
|---|---|---|---|---|
| 1y | +6.80% | — | — | 2025-10-23 → today · 1.0y |
| 3y | +17.29% | — | — | 2023-10-23 → today · 3.0y |
Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).
Rolling 1-year returns distribution · 893 daily entry points · last 5 years
Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.
Median 1y return
+16.7%
Mean 1y return
+20.3%
Best / worst 1y
+56.4% / -5.2%
Windows positive
92%
Longer rolling windows · annualised
Same idea over longer holding periods. Returns are CAGR (annualised) so they're directly comparable to the trailing-CAGR table above.
| Period | Median | Mean | Worst | Best | % positive | Windows |
|---|---|---|---|---|---|---|
| 3y rolling | +20.1% | +20.1% | +13.9% | +23.8% | 100% | 403 |
Beat-benchmark consistency · vs assigned benchmark, across overlapping windows
Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.
| Period | Windows beat | Total windows | % beat | Avg excess (annualised) |
|---|---|---|---|---|
| 1y rolling | 299 | 590 | 51% | -1.0% |
| 3y rolling | 49 | 99 | 49% | +0.3% |
Monthly returns · since inception (Mar 2022)
How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.9 | +5.4 | -10.0 | +10.5 | +1.7 | +1.5 | +4.4 | +3.7 | -2.3 | -5.2 | · | · | +5.4 |
| 2025 | -6.7 | -10.7 | +10.7 | +1.5 | +5.9 | +3.3 | -0.8 | -1.5 | +3.1 | +3.7 | -0.5 | +1.0 | +7.5 |
| 2024 | +2.5 | +3.7 | +3.6 | +3.9 | +4.3 | +7.8 | +3.8 | -1.2 | +2.1 | -7.2 | +0.1 | +0.6 | +25.9 |
| 2023 | +0.1 | -2.3 | +0.0 | +3.8 | +3.3 | +6.1 | +5.3 | +1.5 | +0.7 | -3.3 | +7.0 | +6.6 | +32.2 |
| 2022 | · | · | · | +1.2 | -1.2 | -3.0 | +8.0 | +4.7 | -2.9 | +2.6 | +0.6 | -3.0 | +6.6 |
| Avg | -1.7 | -1.0 | +1.1 | +4.2 | +2.8 | +3.2 | +4.2 | +1.4 | +0.1 | -1.0 | +1.8 | +1.3 | +21.9 |
All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (3 complete calendar years in the last column); the running month is left out of it.
Portfolio mix · asset class breakdown as of 2026-09-30
Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings
Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).
- Large Cap 38.6%
- Mid Cap 18.6%
- Small Cap 31.1%
- Cash & Equivalents 3.7%
- ETF / FoF (incl. gold/silver) 0.5%
- Unlisted & other equity 7.5%
12% of the fund sits outside AMFI-classified equity: debt, cash, ETF/FoF units, REITs, foreign holdings, or unlisted/pre-IPO paper.
Index overlap
· vs · share of this fund's AUM that sits in stocks the index also includesNo holdings data yet for this fund.
Top stocks held · 60 holdings as of 2026-09-30 See changes vs previous snapshot →
| Stock | Sector | % of fund |
|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Pharmaceuticals and Biotechnology | 4.35% |
| RUBICON RESEARCH LIMITED | Pharmaceuticals and Biotechnology | 4.31% |
| Divis Laboratories Ltd. | Pharmaceuticals and Biotechnology | 3.71% |
| Mahindra & Mahindra Ltd. | Automobiles | 3.53% |
| Tata Steel Ltd. | Ferrous Metals | 3.41% |
| TVS Motor Company Ltd. | Automobiles | 3.28% |
| INDO-MIM LTD | Industrial Manufacturing | 3.27% |
| DEE DEVELOPMENT ENGINEEERS LTD | Industrial Manufacturing | 2.92% |
| RELIANCE INDUSTRIES LTD. | Petroleum Products | 2.84% |
| Hero MotoCorp Ltd. | Automobiles | 2.68% |
| Bharat Electronics Ltd. | Aerospace and Defense | 2.51% |
| Maruti Suzuki India Limited | Automobiles | 2.48% |
| Graphite India Limited. | Industrial Products | 2.44% |
| Hindalco Industries Ltd. | Non - Ferrous Metals | 2.41% |
| Dixon Technologies India Ltd | Consumer Durables | 2.09% |
| POWERICA LIMITED | Electrical Equipment | 1.94% |
| ADITYA INFOTECH LIMITED | Industrial Manufacturing | 1.84% |
| Eicher Motors Ltd. | Automobiles | 1.71% |
| Solar Industries India Limited | Chemicals and Petrochemicals | 1.67% |
| ROSSELL TECHSYS LTD. | Aerospace and Defense | 1.63% |
Sector mix
- Capital Goods 24.5%
- Automobile and Auto Components 20.8%
- Pharmaceuticals and Biotechnology 18.5%
- Metals & Mining 7.0%
- Aerospace and Defense 6.0%
- Oil Gas & Consumable Fuels 5.3%
- Cement and Cement Products 3.6%
- Other 14.3%
Risk metrics, trailing 3y (733 matched daily returns, 2023-10-25 → 2026-10-21)
Calmar
+0.76
CAGR / |max DD| in window
Risk-free rate assumed 6.0% annualised. Benchmark = Nifty India Manufacturing (assigned by category mapping).
Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.